Context Therapeutics (CNTX) Current Assets (2020 - 2026)

Context Therapeutics has disclosed Current Assets across 7 years of filings, most recently posting $58.5 million for Q1 2026.

• Current Assets for Q1 2026 came in at $58.5 million, down 36.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $58.5 million (down 36.9% YoY), and the FY2025 annual result was $68.4 million, down 30.18% from the prior year.
• Current Assets came in at $58.5 million for Q1 2026 at Context Therapeutics, down from $68.4 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $102.7 million in Q2 2024 to a low of $11.0 million in Q1 2024.
• The 5-year median for Current Assets is $46.9 million (2022), against an average of $56.1 million.
• Across the five-year window, Current Assets jumped 9485.42% in 2022 and tumbled 65.38% in 2024, its largest moves.
• Context Therapeutics' Current Assets stood at $37.9 million in 2022, then tumbled by 57.61% to $16.0 million in 2023, then soared by 510.05% to $97.9 million in 2024, then sank by 30.18% to $68.4 million in 2025, then fell by 14.39% to $58.5 million in 2026.
• The last three Current Assets figures came in at $58.5 million (Q1 2026), $68.4 million (Q4 2025), and $79.1 million (Q3 2025), per Business Quant data.